Cathay Biotech Inc (688065) - Total Assets
Based on the latest financial reports, Cathay Biotech Inc (688065) holds total assets worth CN¥23.45 Billion CNY (≈ $3.43 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See 688065 net assets for net asset value and shareholders' equity analysis.
Cathay Biotech Inc - Total Assets Trend (2016–2024)
This chart illustrates how Cathay Biotech Inc's total assets have evolved over time, based on quarterly financial data.
Cathay Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Cathay Biotech Inc's total assets of CN¥23.45 Billion consist of 38.8% current assets and 61.2% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 28.1% |
| Accounts Receivable | CN¥470.43 Million | 2.5% |
| Inventory | CN¥1.18 Billion | 6.2% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥685.04 Million | 3.6% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Cathay Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see 688065 stock market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Cathay Biotech Inc's current assets represent 38.8% of total assets in 2024, a decrease from 47.8% in 2016.
- Cash Position: Cash and equivalents constituted 28.1% of total assets in 2024, up from 21.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 1.0% in 2016.
- Asset Diversification: The largest asset category is inventory at 6.2% of total assets.
Cathay Biotech Inc Competitors by Total Assets
Key competitors of Cathay Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
XP Chemistries AB
ST:XPC
|
Sweden | Skr40.66 Million |
|
Zangge Holding Co Ltd
SHE:000408
|
China | CN¥16.36 Billion |
|
Shenzhen Chengxin Lithium Group Co Ltd
SHE:002240
|
China | CN¥21.87 Billion |
|
Suzhou Hesheng Special Material Co Ltd
SHE:002290
|
China | CN¥2.02 Billion |
|
Sichuan Chemical Co Ltd
SHE:000155
|
China | CN¥28.26 Billion |
|
Anhui Wanwei Updated High-tech Material Industry Co Ltd
SHG:600063
|
China | CN¥15.59 Billion |
|
Hubei Jianghan New Materials Co. Ltd. A
SHG:603281
|
China | CN¥5.54 Billion |
|
Robertet SA
PA:RBT
|
France | €1.01 Billion |
Cathay Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 6.94 | 2.87 | 19.42 |
| Quick Ratio | 6.16 | 2.33 | 17.64 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥9.84 Billion | CN¥4.44 Billion | CN¥8.01 Billion |
Cathay Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Cathay Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.18 |
| Latest Market Cap to Assets Ratio | 0.26 |
| Asset Growth Rate (YoY) | 1.0% |
| Total Assets | CN¥19.02 Billion |
| Market Capitalization | $5.02 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Cathay Biotech Inc's assets below their book value (0.26x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: Cathay Biotech Inc's assets grew by 1.0% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for Cathay Biotech Inc (2016–2024)
The table below shows the annual total assets of Cathay Biotech Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥19.02 Billion ≈ $2.78 Billion |
+1.00% |
| 2023-12-31 | CN¥18.83 Billion ≈ $2.76 Billion |
+5.64% |
| 2022-12-31 | CN¥17.83 Billion ≈ $2.61 Billion |
+10.06% |
| 2021-12-31 | CN¥16.20 Billion ≈ $2.37 Billion |
+33.48% |
| 2020-12-31 | CN¥12.14 Billion ≈ $1.78 Billion |
+102.87% |
| 2019-12-31 | CN¥5.98 Billion ≈ $875.32 Million |
+23.60% |
| 2018-12-31 | CN¥4.84 Billion ≈ $708.19 Million |
+54.45% |
| 2017-12-31 | CN¥3.13 Billion ≈ $458.51 Million |
+88.98% |
| 2016-12-31 | CN¥1.66 Billion ≈ $242.62 Million |
-- |
About Cathay Biotech Inc
Cathay Biotech Inc., together with its subsidiaries, engages in the research, development, production, and sale of bio-based materials in China and internationally. The company offers biological long-chain diacids, including sebacic acid and octadecanedioic acid; bio-based polyamides; and bio-based pentamethylene diamine under the TERRYL and ECOPENT brands. It also provides digital solutions for … Read more